Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) - Related Studies

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

This study is ongoing, but not recruiting participants.

Study NCT00599131. Last updated on May 8, 2008. Information provided by University of Michigan Cancer Center

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer of Larynx

2	Additional conditions recognized in this trial
		Laryngeal Neoplasms

3	More general conditions related to this trial
		Head and Neck Neoplasms
		Laryngeal Diseases
		Neoplasms
		Neoplasms by Site
		Otorhinolaryngologic Diseases
		Otorhinolaryngologic Neoplasms
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms

4	Interventions listed in this trial
		Cisplatin
		Cetuximab
		5-Fluorouracil
		Docetaxel

5	Additional drug interventions recognized in this trial
		Fluorouracil

6	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		University of Michigan Cancer Center